1
|
Calahorra J, Blaya-Cánovas JL, Castellini-Pérez O, Aparicio-Puerta E, Cives-Losada C, Marin JJG, Rementeria M, Cara FE, López-Tejada A, Griñán-Lisón C, Aulicino F, Berger I, Marchal JA, Delgado-Almenta V, Granados-Principal S. Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells. Biomed Pharmacother 2024; 174:116439. [PMID: 38518601 DOI: 10.1016/j.biopha.2024.116439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 03/06/2024] [Accepted: 03/15/2024] [Indexed: 03/24/2024] Open
Abstract
Triple-negative breast cancer (TNBC) is characterised by its aggressiveness and resistance to chemotherapy, demanding the development of effective strategies against its unique characteristics. Derived from lapacho tree bark, β-lapachone (β-LP) selectively targets cancer cells with elevated levels of the detoxifying enzyme NQO1. Hydroxytyrosol (HT) is a phenolic compound derived from olive trees with important anticancer properties that include the inhibition of cancer stem cells (CSCs) and metastatic features in TNBC, as well as relevant antioxidant activities by mechanisms such as the induction of NQO1. We aimed to study whether these compounds could have synergistic anticancer activity in TNBC cells and the possible role of NQO1. For this pourpose, we assessed the impact of β-LP (0.5 or 1.5 μM) and HT (50 and 100 μM) on five TNBC cell lines. We demonstrated that the combination of β-LP and HT exhibits anti-proliferative, pro-apoptotic, and cell cycle arrest effects in several TNBC cells, including docetaxel-resistant TNBC cells. Additionally, it effectively inhibits the self-renewal and clonogenicity of CSCs, modifying their aggressive phenotype. However, the notable impact of the β-LP-HT combination does not appear to be solely associated with the levels of the NQO1 protein and ROS. RNA-Seq analysis revealed that the combination's anticancer activity is linked to a strong induction of endoplasmic reticulum stress and apoptosis through the unfolded protein response. In conclusion, in this study, we demonstrated how the combination of β-LP and HT could offer an affordable, safe, and effective approach against TNBC.
Collapse
Affiliation(s)
- Jesús Calahorra
- UGC de Oncología Médica, Hospital Universitario de Jaén, Jaén 23007, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Granada 18100, Spain; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain.
| | - José L Blaya-Cánovas
- UGC de Oncología Médica, Hospital Universitario de Jaén, Jaén 23007, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Granada 18100, Spain; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain
| | - Olivia Castellini-Pérez
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain
| | - Ernesto Aparicio-Puerta
- Clinical Bioinformatics, Center for Bioinformatics, Saarland University, Saarbrücken 66123, Germany
| | - Candela Cives-Losada
- Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca 37007, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid 28029, Spain
| | - Jose J G Marin
- Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca 37007, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid 28029, Spain
| | - Markel Rementeria
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain
| | - Francisca E Cara
- Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Granada 18100, Spain
| | - Araceli López-Tejada
- Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Granada 18100, Spain; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain; Department of Biochemistry and Molecular Biology 2, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, Granada 18071, Spain
| | - Carmen Griñán-Lisón
- Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Granada 18100, Spain; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain; Department of Biochemistry and Molecular Biology 2, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, Granada 18071, Spain
| | - Francesco Aulicino
- BrisSynBio Bristol Synthetic Biology Centre, Biomedical Sciences, School of Biochemistry, University of Bristol, 1 Tankard's Close, Bristol BS8 1TD, UK
| | - Imre Berger
- BrisSynBio Bristol Synthetic Biology Centre, Biomedical Sciences, School of Biochemistry, University of Bristol, 1 Tankard's Close, Bristol BS8 1TD, UK; Max Planck Bristol Centre for Minimal Biology, School of Chemistry, University of Bristol, Cantock's Close, Bristol BS8 1TS, UK
| | - Juan A Marchal
- Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Granada 18100, Spain
| | - Violeta Delgado-Almenta
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain
| | - Sergio Granados-Principal
- Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Granada 18100, Spain; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada 18016, Spain; Department of Biochemistry and Molecular Biology 2, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, Granada 18071, Spain.
| |
Collapse
|
2
|
López-Tejada A, Griñán-Lisón C, González-González A, Cara FE, Luque RJ, Rosa-Garrido C, Blaya-Cánovas JL, Navarro-Ocón A, Valenzuela-Torres M, Parra-López M, Calahorra J, Blancas I, Marchal JA, Granados-Principal S. TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression. Int J Biol Sci 2023; 19:204-224. [PMID: 36594086 PMCID: PMC9760438 DOI: 10.7150/ijbs.78738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Accepted: 10/24/2022] [Indexed: 11/24/2022] Open
Abstract
In triple-negative breast cancer (TNBC), the pleiotropic NDRG1 (N-Myc downstream regulated gene 1) promotes progression and worse survival, yet contradictory results were documented, and the mechanisms remain unknown. Phosphorylation and localization could drive NDRG1 pleiotropy, nonetheless, their role in TNBC progression and clinical outcome was not investigated. We found enhanced p-NDRG1 (Thr346) by TGFβ1 and explored whether it drives NDRG1 pleiotropy and TNBC progression. In tissue microarrays of 81 TNBC patients, we identified that staining and localization of NDRG1 and p-NDRG1 (Thr346) are biomarkers and risk factors associated with shorter overall survival. We found that TGFβ1 leads NDRG1, downstream of GSK3β, and upstream of NF-κB, to differentially regulate migration, invasion, epithelial-mesenchymal transition, tumor initiation, and maintenance of different populations of cancer stem cells (CSCs), depending on the progression stage of tumor cells, and the combination of TGFβ and GSK3β inhibitors impaired CSCs. The present study revealed the striking importance to assess both total NDRG1 and p-NDRG1 (Thr346) positiveness and subcellular localization to evaluate patient prognosis and their stratification. NDRG1 pleiotropy is driven by TGFβ to differentially promote metastasis and/or maintenance of CSCs at different stages of tumor progression, which could be abrogated by the inhibition of TGFβ and GSK3β.
Collapse
Affiliation(s)
- Araceli López-Tejada
- Department of Biochemistry and Molecular Biology 2, School of Pharmacy, University of Granada, 18011 Granada, Spain.,GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Spain; Conocimiento s/n 18100, Granada. Spain
| | - Carmen Griñán-Lisón
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Spain; Conocimiento s/n 18100, Granada. Spain.,UGC de Oncología Médica, Hospital Universitario de Jaén, 23007 Jaén, Spain
| | - Adrián González-González
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
| | - Francisca E. Cara
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
| | - Rafael J. Luque
- UGC de Anatomía Patológica, Hospital Universitario de Jaén, Jaén, Spain
| | - Carmen Rosa-Garrido
- FIBAO, Hospital Universitario de Jaén, Servicio Andaluz de Salud, Jaén, Spain
| | - José L. Blaya-Cánovas
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Spain; Conocimiento s/n 18100, Granada. Spain.,UGC de Oncología Médica, Hospital Universitario de Jaén, 23007 Jaén, Spain
| | - Alba Navarro-Ocón
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Spain; Conocimiento s/n 18100, Granada. Spain
| | - María Valenzuela-Torres
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
| | - Marisa Parra-López
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
| | - Jesús Calahorra
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Spain; Conocimiento s/n 18100, Granada. Spain.,UGC de Oncología Médica, Hospital Universitario de Jaén, 23007 Jaén, Spain
| | - Isabel Blancas
- Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Spain; Conocimiento s/n 18100, Granada. Spain.,UGC de Oncología, Hospital Universitario “San Cecilio”, 18016 Granada, Spain
| | - Juan A. Marchal
- Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Spain; Conocimiento s/n 18100, Granada. Spain.,Department of Human Anatomy and Embryology, Biopathology and Regenerative Medicine Institute (IBIMER), University of Granada, 18011 Granada, Spain.,Excellence Research Unit “Modeling Nature” (MNat), University of Granada, Spain
| | - Sergio Granados-Principal
- Department of Biochemistry and Molecular Biology 2, School of Pharmacy, University of Granada, 18011 Granada, Spain.,GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Spain; Conocimiento s/n 18100, Granada. Spain.,✉ Corresponding author: E-mail: . Phone number: +34 651 55 79 21
| |
Collapse
|
3
|
Navarro-Ocón A, Blaya-Cánovas JL, López-Tejada A, Blancas I, Sánchez-Martín RM, Garrido MJ, Griñán-Lisón C, Calahorra J, Cara FE, Ruiz-Cabello F, Marchal JA, Aptsiauri N, Granados-Principal S. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer. Pharmaceutics 2022; 14:pharmaceutics14030505. [PMID: 35335881 PMCID: PMC8950730 DOI: 10.3390/pharmaceutics14030505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 02/15/2022] [Accepted: 02/23/2022] [Indexed: 12/13/2022] Open
Abstract
Breast cancer is the most common type of malignancy and leading cause of cancer death among women worldwide. Despite the current revolutionary advances in the field of cancer immunotherapy, clinical response in breast cancer is frequently below expectations, in part due to various mechanisms of cancer immune escape that produce tumor variants that are resistant to treatment. Thus, a further understanding of the molecular events underlying immune evasion in breast cancer may guarantee a significant improvement in the clinical success of immunotherapy. Furthermore, nanomedicine provides a promising opportunity to enhance the efficacy of cancer immunotherapy by improving the delivery, retention and release of immunostimulatory agents in targeted cells and tumor tissues. Hence, it can be used to overcome tumor immune escape and increase tumor rejection in numerous malignancies, including breast cancer. In this review, we summarize the current status and emerging trends in nanomedicine-based strategies targeting cancer immune evasion and modulating the immunosuppressive tumor microenvironment, including the inhibition of immunosuppressive cells in the tumor area, the activation of dendritic cells and the stimulation of the specific antitumor T-cell response.
Collapse
Affiliation(s)
- Alba Navarro-Ocón
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (A.N.-O.); (J.L.B.-C.); (A.L.-T.); (R.M.S.-M.); (C.G.-L.); (J.C.); (F.E.C.)
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
| | - Jose L. Blaya-Cánovas
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (A.N.-O.); (J.L.B.-C.); (A.L.-T.); (R.M.S.-M.); (C.G.-L.); (J.C.); (F.E.C.)
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
- UGC de Oncología Médica, Complejo Hospitalario de Jaen, 23007 Jaen, Spain
| | - Araceli López-Tejada
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (A.N.-O.); (J.L.B.-C.); (A.L.-T.); (R.M.S.-M.); (C.G.-L.); (J.C.); (F.E.C.)
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
- Department of Biochemistry and Molecular Biology 2, School of Pharmacy, University of Granada, 18011 Granada, Spain
| | - Isabel Blancas
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
- UGC de Oncología, Hospital Universitario “San Cecilio”, 18016 Granada, Spain
| | - Rosario M. Sánchez-Martín
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (A.N.-O.); (J.L.B.-C.); (A.L.-T.); (R.M.S.-M.); (C.G.-L.); (J.C.); (F.E.C.)
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
| | - María J. Garrido
- Department of Pharmaceutical Technology and Chemistry, School of Pharmacy & Nutrition, Navarra Institute for Health Research (IdisNA), University of Navarra, 31080 Pamplona, Spain;
| | - Carmen Griñán-Lisón
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (A.N.-O.); (J.L.B.-C.); (A.L.-T.); (R.M.S.-M.); (C.G.-L.); (J.C.); (F.E.C.)
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
- UGC de Oncología Médica, Complejo Hospitalario de Jaen, 23007 Jaen, Spain
| | - Jesús Calahorra
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (A.N.-O.); (J.L.B.-C.); (A.L.-T.); (R.M.S.-M.); (C.G.-L.); (J.C.); (F.E.C.)
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
- UGC de Oncología Médica, Complejo Hospitalario de Jaen, 23007 Jaen, Spain
| | - Francisca E. Cara
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (A.N.-O.); (J.L.B.-C.); (A.L.-T.); (R.M.S.-M.); (C.G.-L.); (J.C.); (F.E.C.)
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
| | - Francisco Ruiz-Cabello
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
- Department of Biochemistry, Molecular Biology 3 and Immunology, School of Medicine, University of Granada, 18071 Granada, Spain
| | - Juan A. Marchal
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
- Department of Human Anatomy and Embryology, School of Medicine, University of Granada, 18016 Granada, Spain
| | - Natalia Aptsiauri
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
- Department of Biochemistry, Molecular Biology 3 and Immunology, School of Medicine, University of Granada, 18071 Granada, Spain
- Correspondence: (N.A.); (S.G.-P.)
| | - Sergio Granados-Principal
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (A.N.-O.); (J.L.B.-C.); (A.L.-T.); (R.M.S.-M.); (C.G.-L.); (J.C.); (F.E.C.)
- Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain; (I.B.); (F.R.-C.); (J.A.M.)
- Department of Biochemistry and Molecular Biology 2, School of Pharmacy, University of Granada, 18011 Granada, Spain
- Correspondence: (N.A.); (S.G.-P.)
| |
Collapse
|
4
|
Griñan-Lison C, Blaya-Cánovas JL, López-Tejada A, Ávalos-Moreno M, Navarro-Ocón A, Cara FE, González-González A, Lorente JA, Marchal JA, Granados-Principal S. Antioxidants for the Treatment of Breast Cancer: Are We There Yet? Antioxidants (Basel) 2021; 10:antiox10020205. [PMID: 33572626 PMCID: PMC7911462 DOI: 10.3390/antiox10020205] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 01/27/2021] [Accepted: 01/28/2021] [Indexed: 12/15/2022] Open
Abstract
Breast cancer is the most frequent cancer and the leading cause of cancer death in women. Oxidative stress and the generation of reactive oxygen species (ROS) have been related to cancer progression. Compared to their normal counterparts, tumor cells show higher ROS levels and tight regulation of REDOX homeostasis to maintain a low degree of oxidative stress. Traditionally antioxidants have been extensively investigated to counteract breast carcinogenesis and tumor progression as chemopreventive agents; however, there is growing evidence indicating their potential as adjuvants for the treatment of breast cancer. Aimed to elucidate whether antioxidants could be a reality in the management of breast cancer patients, this review focuses on the latest investigations regarding the ambivalent role of antioxidants in the development of breast cancer, with special attention to the results derived from clinical trials, as well as their potential use as plausible agents in combination therapy and their power to ameliorate the side effects attributed to standard therapeutics. Data retrieved herein suggest that antioxidants play an important role in breast cancer prevention and the improvement of therapeutic efficacy; nevertheless, appropriate patient stratification based on “redoxidomics” or tumor subtype is mandatory in order to define the dosage for future standardized and personalized treatments of patients.
Collapse
Affiliation(s)
- Carmen Griñan-Lison
- Centre for Biomedical Research (CIBM), Biopathology and Regenerative Medicine Institute (IBIMER), University of Granada, 18100 Granada, Spain; (C.G.-L.); (J.A.M.)
- Instituto de Investigación Biosanitaria Ibs.GRANADA, University Hospitals of Granada-University of Granada, 18100 Granada, Spain
- Excellence Research Unit “Modeling Nature” (MNat), University of Granada, 18100 Granada, Spain
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (J.L.B.-C.); (A.L.-T.); (M.Á.-M.); (A.N.-O.); (F.E.C.); (A.G.-G.); (J.A.L.)
| | - Jose L. Blaya-Cánovas
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (J.L.B.-C.); (A.L.-T.); (M.Á.-M.); (A.N.-O.); (F.E.C.); (A.G.-G.); (J.A.L.)
| | - Araceli López-Tejada
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (J.L.B.-C.); (A.L.-T.); (M.Á.-M.); (A.N.-O.); (F.E.C.); (A.G.-G.); (J.A.L.)
| | - Marta Ávalos-Moreno
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (J.L.B.-C.); (A.L.-T.); (M.Á.-M.); (A.N.-O.); (F.E.C.); (A.G.-G.); (J.A.L.)
| | - Alba Navarro-Ocón
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (J.L.B.-C.); (A.L.-T.); (M.Á.-M.); (A.N.-O.); (F.E.C.); (A.G.-G.); (J.A.L.)
| | - Francisca E. Cara
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (J.L.B.-C.); (A.L.-T.); (M.Á.-M.); (A.N.-O.); (F.E.C.); (A.G.-G.); (J.A.L.)
| | - Adrián González-González
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (J.L.B.-C.); (A.L.-T.); (M.Á.-M.); (A.N.-O.); (F.E.C.); (A.G.-G.); (J.A.L.)
| | - Jose A. Lorente
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (J.L.B.-C.); (A.L.-T.); (M.Á.-M.); (A.N.-O.); (F.E.C.); (A.G.-G.); (J.A.L.)
- Department of Legal Medicine, School of Medicine, University of Granada, 18016 Granada, Spain
| | - Juan A. Marchal
- Centre for Biomedical Research (CIBM), Biopathology and Regenerative Medicine Institute (IBIMER), University of Granada, 18100 Granada, Spain; (C.G.-L.); (J.A.M.)
- Instituto de Investigación Biosanitaria Ibs.GRANADA, University Hospitals of Granada-University of Granada, 18100 Granada, Spain
- Excellence Research Unit “Modeling Nature” (MNat), University of Granada, 18100 Granada, Spain
- Department of Human Anatomy and Embryology, School of Medicine, University of Granada, 18016 Granada, Spain
| | - Sergio Granados-Principal
- Instituto de Investigación Biosanitaria Ibs.GRANADA, University Hospitals of Granada-University of Granada, 18100 Granada, Spain
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain; (J.L.B.-C.); (A.L.-T.); (M.Á.-M.); (A.N.-O.); (F.E.C.); (A.G.-G.); (J.A.L.)
- Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18011 Granada, Spain
- Correspondence: or ; Tel.: +34-651-55-79-21
| |
Collapse
|
5
|
Carrillo‐Gálvez AB, Gálvez‐Peisl S, González‐Correa JE, de Haro‐Carrillo M, Ayllón V, Carmona‐Sáez P, Ramos‐Mejía V, Galindo‐Moreno P, Cara FE, Granados‐Principal S, Muñoz P, Martin F, Anderson P. GARP is a key molecule for mesenchymal stromal cell responses to TGF-β and fundamental to control mitochondrial ROS levels. Stem Cells Transl Med 2020; 9:636-650. [PMID: 32073751 PMCID: PMC7180295 DOI: 10.1002/sctm.19-0372] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Accepted: 01/23/2020] [Indexed: 12/15/2022] Open
Abstract
Multipotent mesenchymal stromal cells (MSCs) have emerged as a promising cell therapy in regenerative medicine and for autoimmune/inflammatory diseases. However, a main hurdle for MSCs-based therapies is the loss of their proliferative potential in vitro. Here we report that glycoprotein A repetitions predominant (GARP) is required for the proliferation and survival of adipose-derived MSCs (ASCs) via its regulation of transforming growth factor-β (TGF-β) activation. Silencing of GARP in human ASCs increased their activation of TGF-β which augmented the levels of mitochondrial reactive oxygen species (mtROS), resulting in DNA damage, a block in proliferation and apoptosis. Inhibition of TGF-β signaling reduced the levels of mtROS and DNA damage and restored the ability of GARP-/low ASCs to proliferate. In contrast, overexpression of GARP in ASCs increased their proliferative capacity and rendered them more resistant to etoposide-induced DNA damage and apoptosis, in a TGF-β-dependent manner. In summary, our data show that the presence or absence of GARP on ASCs gives rise to distinct TGF-β responses with diametrically opposing effects on ASC proliferation and survival.
Collapse
Affiliation(s)
- Ana Belén Carrillo‐Gálvez
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
| | - Sheyla Gálvez‐Peisl
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
| | - Juan Elías González‐Correa
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
| | - Marina de Haro‐Carrillo
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
| | - Verónica Ayllón
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
| | - Pedro Carmona‐Sáez
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
| | - Verónica Ramos‐Mejía
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
| | - Pablo Galindo‐Moreno
- Department of Oral Surgery and Implant DentistrySchool of Dentistry, University of GranadaGranadaSpain
| | - Francisca E. Cara
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
- UGC de Oncología Médica, Hospital Universitario de JaénJaénSpain
| | - Sergio Granados‐Principal
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
- UGC de Oncología Médica, Hospital Universitario de JaénJaénSpain
| | - Pilar Muñoz
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
| | - Francisco Martin
- Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalucian Regional GovernmentGranadaSpain
| | - Per Anderson
- Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio ClínicoHospital Universitario Virgen de las NievesGranadaSpain
- Biosanitary Institute of Granada (ibs.Granada), University of GranadaSpain
| |
Collapse
|
6
|
Cruz-Lozano M, González-González A, Marchal JA, Muñoz-Muela E, Molina MP, Cara FE, Brown AM, García-Rivas G, Hernández-Brenes C, Lorente JA, Sanchez-Rovira P, Chang JC, Granados-Principal S. Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways. Eur J Nutr 2018; 58:3207-3219. [DOI: 10.1007/s00394-018-1864-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Accepted: 11/14/2018] [Indexed: 02/07/2023]
|
7
|
González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clin Cancer Res 2018; 24:5697-5709. [PMID: 30012564 DOI: 10.1158/1078-0432.ccr-17-3125] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Revised: 04/30/2018] [Accepted: 07/11/2018] [Indexed: 11/16/2022]
Abstract
Purpose: On the basis of the identified stress-independent cellular functions of activating transcription factor 4 (ATF4), we reported enhanced ATF4 levels in MCF10A cells treated with TGFβ1. ATF4 is overexpressed in patients with triple-negative breast cancer (TNBC), but its impact on patient survival and the underlying mechanisms remain unknown. We aimed to determine ATF4 effects on patients with breast cancer survival and TNBC aggressiveness, and the relationships between TGFβ and ATF4. Defining the signaling pathways may help us identify a cell signaling-tailored gene signature.Experimental Design: Patient survival data were determined by Kaplan-Meier analysis. Relationship between TGFβ and ATF4, their effects on aggressiveness (tumor proliferation, metastasis, and stemness), and the underlying pathways were analyzed in three TNBC cell lines and in vivo using patient-derived xenografts (PDX).Results: ATF4 overexpression correlated with TNBC patient survival decrease and a SMAD-dependent crosstalk between ATF4 and TGFβ was identified. ATF4 expression inhibition reduced migration, invasiveness, mammosphere-forming efficiency, proliferation, epithelial-mesenchymal transition, and antiapoptotic and stemness marker levels. In PDX models, ATF4 silencing decreased metastases, tumor growth, and relapse after chemotherapy. ATF4 was shown to be active downstream of SMAD2/3/4 and mTORC2, regulating TGFβ/SMAD and mTOR/RAC1-RHOA pathways independently of stress. We defined an eight-gene signature with prognostic potential, altered in 45% of 2,509 patients with breast cancer.Conclusions: ATF4 may represent a valuable prognostic biomarker and therapeutic target in patients with TNBC, and we identified a cell signaling pathway-based gene signature that may contribute to the development of combinatorial targeted therapies for breast cancer. Clin Cancer Res; 24(22); 5697-709. ©2018 AACR.
Collapse
Affiliation(s)
- Adrián González-González
- UGC de Oncología Médica, Complejo Hospitalario de Jaén, Jaén, Spain.,GENYO, Centre for Genomics and Oncological Research, Granada, Spain
| | - Esperanza Muñoz-Muela
- UGC de Oncología Médica, Complejo Hospitalario de Jaén, Jaén, Spain.,GENYO, Centre for Genomics and Oncological Research, Granada, Spain
| | - Juan A Marchal
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Universidad de Granada, Granada, Spain.,Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada, Spain
| | - Francisca E Cara
- UGC de Oncología Médica, Complejo Hospitalario de Jaén, Jaén, Spain.,GENYO, Centre for Genomics and Oncological Research, Granada, Spain
| | - Maria P Molina
- UGC de Oncología Médica, Complejo Hospitalario de Jaén, Jaén, Spain.,GENYO, Centre for Genomics and Oncological Research, Granada, Spain
| | - Marina Cruz-Lozano
- UGC de Oncología Médica, Complejo Hospitalario de Jaén, Jaén, Spain.,GENYO, Centre for Genomics and Oncological Research, Granada, Spain
| | - Gema Jiménez
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Universidad de Granada, Granada, Spain.,Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada, Spain
| | - Akanksha Verma
- Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York
| | - Alberto Ramírez
- Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas
| | - Wei Qian
- Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York
| | - Wen Chen
- Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas
| | | | - Olivier Elemento
- Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York
| | | | - Rafael J Luque
- UGC de Anatomía Patológica, Complejo Hospitalario de Jaén, Jaén, Spain
| | - Carmen Rosa-Garrido
- FIBAO. Complejo Hospitalario de Jaén, Servicio Andaluz de Salud, Jaén, Spain
| | - David Landeira
- GENYO, Centre for Genomics and Oncological Research, Granada, Spain.,Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada, Spain
| | - María Quintana-Romero
- GENYO, Centre for Genomics and Oncological Research, Granada, Spain.,Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada, Spain
| | - Roberto R Rosato
- Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas
| | - Maria A García
- Department of Oncology, Virgen de las Nieves University Hospital, Granada, Spain
| | | | - Hanna Kim
- Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, Texas
| | - Cristian Rodriguez-Aguayo
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Gabriel Lopez-Berestein
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Anil K Sood
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Jose A Lorente
- GENYO, Centre for Genomics and Oncological Research, Granada, Spain
| | - Pedro Sánchez-Rovira
- UGC de Oncología Médica, Complejo Hospitalario de Jaén, Jaén, Spain.,GENYO, Centre for Genomics and Oncological Research, Granada, Spain
| | - Jenny C Chang
- Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas
| | - Sergio Granados-Principal
- UGC de Oncología Médica, Complejo Hospitalario de Jaén, Jaén, Spain. .,GENYO, Centre for Genomics and Oncological Research, Granada, Spain.,FIBAO. Complejo Hospitalario de Jaén, Servicio Andaluz de Salud, Jaén, Spain
| |
Collapse
|
8
|
Chang JC, Ramirez A, Molina MP, Cara FE, Qian W, Chen W, Kozielski AJ, Rosato RR, Marchal JA, Lorente JA, Sanchez-Rovira P, Granados-Principal S. Abstract 2035: Knockdown of TGFβ-activated ATF4 inhibits triple negative breast cancer metastases independently of cellular stress. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-2035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Triple negative breast cancer (TNBC) is a very aggressive form of breast cancer which is characterized by a poor survival rate and high incidence of metastases. The integrated stress response (ISR) is activated under stress conditions (hypoxia, nutrient deprivation, or endoplasmic reticulum stress) and reduces the protein synthesis through phospho-eIF2α/ATF4 (activating transcription factor 4) to regulate cell fate. ATF4, which is overexpressed in breast cancer including TNBC, regulates tumor growth, autophagy, drug resistance, and metastasis during ISR through PERK and GCN2 pathways. We have reported enhanced ATF4 expression in unstressed MCF10A cells treated with TGFβ1. Here, we investigate the potential TGFβ-mediated stress-independent control of ATF4 activity and its impact on the TNBC-associated metastasis.
Methods. SUM159PT and BT549 TNBC cell lines were treated with human recombinant TGFβ1 (10 ng/ml) and the TGFBRI kinase inhibitor LY2157299 (5µM) for 72h. Effects of TGFβ on ATF4 expression were assessed by silencing SMAD2/3 and SMAD4 with TGFβ1 for 24h in SUM159PT and BT549 cells. Changes in ATF4 expression by IRS were assessed after PERK, GCN2, PKR, HRI, and eIF2α inhibition with TGFβ1 for 72h in SUM159PT, BT549 and MDA-MB-231 cell lines. ATF4 expression levels were determined by RT-PCR and/or western blot. Effects on TGFβ-induced metastasis were analyzed by ATF4 knockdown for 48h by using two different siRNA sequences (#1 and #2) following treatment with TGFβ1 for 24h. Migration and invasion were performed by wound healing and transwell assays, respectively. Results were compared to a scrambled siRNA as negative control (SCR).
Results. Our results show that ATF4 expression (at RNA and protein levels) was abrogated by LY2157299 upon TGFβ activation, suggesting that ATF4 is active downstream of TGFBRI. This result was supported by further SMAD2/3 and SMAD4 knockdown following treatment with TGFβ1, which was correlated with decreased ATF4 expression. Additionally, we assessed whether ATF4 inhibition can reduce the TGFβ-induced metastatic properties of TNCB cell lines. We found that ATF4 depletion inhibited migration and invasiveness in the three cell lines tested. ATF4 is known to exert a pro-metastatic role downstream of ISR through PERK and GCN2 pathways. Our results demonstrate that, upon treatment with TGFβ1, knockdown of the IRS mediators PERK, PKR, GCN2, HRI, and eIF2α did not correlate with a consistent decrease of ATF4 levels in the three cell lines.
Conclusion. In conclusion, our results show for the first time that ATF4 is a downstream target of the canonical TGFβ/SMAD pathway in a ISR-independent fashion, and its depletion correlates with an inhibition of the TGFβ1-mediated migration and invasion of TNBC cell lines. Therefore, ATF4 may represent a therapeutic target in TNBC patients with active TGFβ signaling pathway.
Citation Format: Jenny C. Chang, Alberto Ramirez, Maria P. Molina, Francisca E. Cara, Wei Qian, Wen Chen, Anthony J. Kozielski, Roberto R. Rosato, Juan A. Marchal, Jose A. Lorente, Pedro Sanchez-Rovira, Sergio Granados-Principal. Knockdown of TGFβ-activated ATF4 inhibits triple negative breast cancer metastases independently of cellular stress [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2035.
Collapse
Affiliation(s)
| | | | | | | | - Wei Qian
- 1Houston Methodist Research Institute, Houston, TX
| | - Wen Chen
- 1Houston Methodist Research Institute, Houston, TX
| | | | | | | | - Jose A. Lorente
- 4GENYO, Centre for Genomics and Oncological Research (Pfizer / University of Granada / Andalusian Regional Government), Granada, Spain
| | | | | |
Collapse
|
9
|
Segura-Ibarra V, Cara FE, Wu S, Iruegas-Nunez DA, Wang S, Ferrari M, Ziemys A, Valderrabano M, Blanco E. Nanoparticles administered intrapericardially enhance payload myocardial distribution and retention. J Control Release 2017; 262:18-27. [PMID: 28700900 DOI: 10.1016/j.jconrel.2017.07.012] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Revised: 07/04/2017] [Accepted: 07/07/2017] [Indexed: 12/15/2022]
Abstract
Pharmacological therapies for cardiovascular diseases are limited by short-term pharmacokinetics and extra-cardiac adverse effects. Improving delivery selectivity specifically to the heart, wherein therapeutic drug levels can be maintained over time, is highly desirable. Nanoparticle (NP)-based pericardial drug delivery could provide a strategy to concentrate therapeutics within a unique, cardiac-restricted compartment to allow sustained drug penetration into the myocardium. Our objective was to explore the kinetics of myocardial penetration and retention after pericardial NP drug delivery. Fluorescently-tagged poly(lactic-co-glycolic acid) (PLGA) NPs were loaded with BODIPY, a fluorophore, and percutaneously administered into the pericardium via subxiphoid puncture in rabbits. At distinct timepoints hearts were examined for presence of NPs and BODIPY. PLGA NPs were found non-uniformly distributed on the epicardium following pericardial administration, displaying a half-life of ~2.5days in the heart. While NPs were mostly confined to epicardial layers, BODIPY was capable of penetrating into the myocardium, resulting in a transmural gradient. The distinct architecture and physiology of the different regions of the heart influenced BODIPY distribution, with fluorophore penetrating more readily into atria than ventricles. BODIPY proved to have a long-term presence within the heart, with a half-life of ~7days. Our findings demonstrate the potential of utilizing the pericardial space as a sustained drug-eluting reservoir through the application of nanoparticle-based drug delivery, opening several exciting avenues for selective and prolonged cardiac therapeutics.
Collapse
Affiliation(s)
- Victor Segura-Ibarra
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Monterrey, NL 64710, Mexico
| | - Francisca E Cara
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
| | - Suhong Wu
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
| | - David A Iruegas-Nunez
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Monterrey, NL 64710, Mexico
| | - Sufen Wang
- Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
| | - Arturas Ziemys
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
| | - Miguel Valderrabano
- Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA.
| | - Elvin Blanco
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
| |
Collapse
|
10
|
Segura-Ibarra V, Amione-Guerra J, Cruz-Solbes AS, Cara FE, Iruegas-Nunez DA, Wu S, Youker KA, Bhimaraj A, Torre-Amione G, Ferrari M, Karmouty-Quintana H, Guha A, Blanco E. Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension. Int J Pharm 2017; 524:257-267. [PMID: 28359821 DOI: 10.1016/j.ijpharm.2017.03.069] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 03/22/2017] [Accepted: 03/26/2017] [Indexed: 12/24/2022]
Abstract
Vascular remodeling resulting from pulmonary arterial hypertension (PAH) leads to endothelial fenestrations. This feature can be exploited by nanoparticles (NP), allowing them to extravasate from circulation and accumulate in remodeled pulmonary vessels. Hyperactivation of the mTOR pathway in PAH drives pulmonary arterial smooth muscle cell proliferation. We hypothesized that rapamycin (RAP)-loaded NPs, an mTOR inhibitor, would accumulate in diseased lungs, selectively targeting vascular mTOR and preventing PAH progression. RAP poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL) NPs were fabricated. NP accumulation and efficacy were examined in a rat monocrotaline model of PAH. Following intravenous (IV) administration, NP accumulation in diseased lungs was verified via LC/MS analysis and confocal imaging. Pulmonary arteriole thickness, right ventricular systolic pressures, and ventricular remodeling were determined to assess the therapeutic potential of RAP NPs. Monocrotaline-exposed rats showed increased NP accumulation within lungs compared to healthy controls, with NPs present to a high extent within pulmonary perivascular regions. RAP, in both free and NP form, attenuated PAH development, with histological analysis revealing minimal changes in pulmonary arteriole thickness and no ventricular remodeling. Importantly, NP-treated rats showed reduced systemic side effects compared to free RAP. This study demonstrates the potential for nanoparticles to significantly impact PAH through site-specific delivery of therapeutics.
Collapse
Affiliation(s)
- Victor Segura-Ibarra
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Monterrey, NL 64710, Mexico.
| | - Javier Amione-Guerra
- Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA.
| | - Ana S Cruz-Solbes
- Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA.
| | - Francisca E Cara
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
| | - David A Iruegas-Nunez
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Monterrey, NL 64710, Mexico.
| | - Suhong Wu
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
| | - Keith A Youker
- Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA.
| | - Arvind Bhimaraj
- Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA.
| | - Guillermo Torre-Amione
- Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA; Catedra de Cardiología y Medicina Vascular, Tecnológico de Monterrey, Monterrey, NL 66278, Mexico.
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
| | - Harry Karmouty-Quintana
- Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
| | - Ashrith Guha
- Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA.
| | - Elvin Blanco
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
| |
Collapse
|
11
|
Ruiz-Esparza GU, Segura-Ibarra V, Cordero-Reyes AM, Youker KA, Serda RE, Cruz-Solbes AS, Amione-Guerra J, Yokoi K, Kirui DK, Cara FE, Paez-Mayorga J, Flores-Arredondo JH, Guerrero-Beltrán CE, Garcia-Rivas G, Ferrari M, Blanco E, Torre-Amione G. A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics. Eur J Heart Fail 2016; 18:169-78. [PMID: 26749465 DOI: 10.1002/ejhf.463] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Revised: 09/24/2015] [Accepted: 11/12/2015] [Indexed: 12/15/2022] Open
Abstract
AIMS Ongoing inflammation and endothelial dysfunction occurs within the local microenvironment of heart failure, creating an appropriate scenario for successful use and delivery of nanovectors. This study sought to investigate whether cardiovascular cells associate, internalize, and traffic a nanoplatform called mesoporous silicon vector (MSV), and determine its intravenous accumulation in cardiac tissue in a murine model of heart failure. METHODS AND RESULTS In vitro cellular uptake and intracellular trafficking of MSVs was examined by scanning electron microscopy, confocal microscopy, time-lapse microscopy, and flow cytometry in cardiac myocytes, fibroblasts, smooth muscle cells, and endothelial cells. The MSVs were internalized within the first hours, and trafficked to perinuclear regions in all the cell lines. Cytotoxicity was investigated by annexin V and cell cycle assays. No significant evidence of toxicity was found. In vivo intravenous cardiac accumulation of MSVs was examined by high content fluorescence and confocal microscopy, with results showing increased accumulation of particles in failing hearts compared with normal hearts. Similar to observations in vitro, MSVs were able to associate, internalize, and traffic to the perinuclear region of cardiomyocytes in vivo. CONCLUSIONS Results show that MSVs associate, internalize, and traffic in cardiovascular cells without any significant toxicity. Furthermore, MSVs accumulate in failing myocardium after intravenous administration, reaching intracellular regions of the cardiomyocytes. These findings represent a novel avenue to develop nanotechnology-based therapeutics and diagnostics in heart failure.
Collapse
Affiliation(s)
- Guillermo U Ruiz-Esparza
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA.,Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Monterrey N.L., México 64849.,Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710
| | - Victor Segura-Ibarra
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA.,Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Monterrey N.L., México 64849
| | - Andrea M Cordero-Reyes
- DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| | - Keith A Youker
- DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| | - Rita E Serda
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
| | - Ana S Cruz-Solbes
- DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| | - Javier Amione-Guerra
- DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| | - Kenji Yokoi
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA
| | - Dickson K Kirui
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA
| | - Francisca E Cara
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA
| | - Jesus Paez-Mayorga
- Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710
| | - Jose H Flores-Arredondo
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
| | - Carlos E Guerrero-Beltrán
- Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710
| | - Gerardo Garcia-Rivas
- Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA.,Department of Medicine, Weill Cornell Medical College New York, NY, 10021, USA
| | - Elvin Blanco
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA
| | - Guillermo Torre-Amione
- Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710.,DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| |
Collapse
|
12
|
Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, Cara FE, Granados-Principal S, Evans KW, Akcakanat A, Wang Y, Do KA, Meric-Bernstam F, Ferrari M. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther 2014; 22:1310-1319. [PMID: 24569835 DOI: 10.1038/mt.2014.27] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2013] [Accepted: 02/13/2014] [Indexed: 12/19/2022] Open
Abstract
Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel. However, synergy may not be fully exploited clinically because of distinct pharmacokinetic parameters of drugs. This study explores the synergistic potential of site-specific, colocalized delivery of rapamycin and paclitaxel through nanoparticle incorporation. Nanoparticle drug loading was accurately controlled, and synergistic drug ratios established in vitro. Precise drug ratios were maintained in tumors 48 hours after nanoparticle administration to mice, at levels twofold greater than liver and spleen, yielding superior antitumor activity compared to controls. Simultaneous and preferential in vivo delivery of rapamycin and paclitaxel to tumors yielded mechanistic insights into synergy involving suppression of feedback loop Akt phosphorylation and its downstream targets. Findings demonstrate that a same time, same place, and specific amount approach to combination chemotherapy by means of nanoparticle delivery has the potential to successfully translate in vitro synergistic findings in vivo. Predictive in vitro models can be used to determine optimum drug ratios for antitumor efficacy, while nanoparticle delivery of combination chemotherapies in preclinical animal models may lead to enhanced understanding of mechanisms of synergy, ultimately opening several avenues for personalized therapy.
Collapse
Affiliation(s)
- Elvin Blanco
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA
| | - Takafumi Sangai
- Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Suhong Wu
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA
| | - Angela Hsiao
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA
| | - Guillermo U Ruiz-Esparza
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA; Escuela de Biotecnología y Alimentos y Escuela de Medicina, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico
| | - Carlos A Gonzalez-Delgado
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA; Escuela de Biotecnología y Alimentos y Escuela de Medicina, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico
| | - Francisca E Cara
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA
| | | | - Kurt W Evans
- Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Argun Akcakanat
- Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Ying Wang
- Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Kim-Anh Do
- Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Funda Meric-Bernstam
- Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
| | - Mauro Ferrari
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA.
| |
Collapse
|